| Literature DB >> 34234946 |
Daisuke Takei1, Shintaro Kuroda1, Keiso Matsubara1, Hiroaki Mashima1, Masakazu Hashimoto1, Tsuyoshi Kobayashi1, Hideki Ohdan1.
Abstract
BACKGROUND: While the adoption rates of laparoscopic hepatectomy are increasing, most patients still undergo open hepatectomy. Open hepatectomies use inverted L-shaped or Mercedes incisions for right-sided liver tumor. To decrease procedural invasiveness, we performed midline incisions in such cases, excluding those of laparoscopic hepatectomy. This retrospective study examined the effects of this change in treatment policy on overall patient surgical outcomes.Entities:
Keywords: Hepatectomy; Hepatocellular carcinoma; Liver cancer; Midline incision; Post-operative pain
Year: 2021 PMID: 34234946 PMCID: PMC8246149 DOI: 10.1016/j.amsu.2021.102498
Source DB: PubMed Journal: Ann Med Surg (Lond) ISSN: 2049-0801
Fig. 1Change in the institutional treatment policy
The first-choice surgical strategy is laparoscopic surgery; however, since January 2015, laparotomies were performed utilizing midline incisions where possible.
Fig. 2Surgical procedure for hepatectomy utilizing an upper midline incision for right-sided liver cancer
(a) The abdominal wall is retracted using the Thompson retractor.
(b) The entire liver is rotated from the right to the left side in order to bring the resection range to just below the wound.
(c) The right adrenal gland is dissected in order to fully mobilize the right lobe.
(d) Postoperative image overview of the wound following right-sided hepatectomy utilizing an upper midline incision.
Clinical characteristics of patients in the 1st Era and 2nd Era groups.
| Variables | Group 1st Era (n = 157) | Group 2nd Era (n = 217) | P-Value |
|---|---|---|---|
| Age | 70 (33–91) | 71 (20–88) | 0.24 |
| Sex; Male/Female | 122/35 | 165/52 | 0.70 |
| BMI | 22.8 (16.5–37.3) | 23.2 (15.5–36.9) | 0.12 |
| DM; Yes/No | 48/68 | 66/113 | 0.43 |
| T-Bil (mg/dl) | 0.8 (0.3–2.9) | 0.8 (0.3–2.7) | 0.76 |
| AST (IU/l) | 36 (11–296) | 31 (12–390) | <0.05 |
| Albumin (mg/dl) | 4.1 (2.3–5.1) | 4.0 (2.5–7.4) | 0.92 |
| Prothrombin time (%) | 84 (24–112) | 90 (24–145) | <0.01 |
| ICGR-15 (%) | 13.8 (2.6–79.1) | 13.2 (2.2–79.2) | 0.85 |
| Child-Pugh classification; A/B | 143/14 | 205/12 | 0.20 |
| AFP (ng/ml) | 14 (0.5–11234) | 7 (0.5–290700) | <0.05 |
| Tumor size (mm) | 25 (8–170) | 25 (8–200) | 0.73 |
| Tumor number; Single/Multiple | 97/60 | 133/84 | 0.92 |
| Liver cirrhosis; Yes/No | 36/121 | 39/178 | 0.23 |
| Posterior region; Yes/No | 71/86 | 113/104 | 0.19 |
| Resected weight (g) | 151 (5–2332) | 137 (6–2903) | 0.79 |
| Type of hepatectomy; Anatomical/Limited | 107/50 | 154/63 | 0.55 |
| Type of hepatectomy; Major/Minor | 16/141 | 22/195 | 0.98 |
| Perioperative pain management; Epi-PCA/iv-PCA | 80/77 | 113/103 | 0.83 |
The 1st Era group (L-shaped incision: n = 123; Midline incision: n = 7; Laparoscopic surgery: n = 27) comprised patients who underwent procedures prior to the institutional policy change. The 2nd Era group (L-shaped incision: n = 66; Midline incision: n = 109; Laparoscopic surgery: n = 42) comprised patients who underwent procedures after the policy change.
BMI, body mass index; DM, diabetes mellitus; T-Bil, total bilirubin; AST, aspartate aminotransferase; ALT, alanine transaminase; ICGR-15, indocyanine green retention rate at 15 min; AFP, α-fetoprotein; Epi-PCA, epidural-patient-controlled analgesia; iv-PCA, intravenous-patient-controlled analgesia.
[median, (range)].
Surgical and postoperative outcomes in the 1st Era and 2nd Era groups.
| Variables | Group 1st Era (n = 157) | Group 2nd Era (n = 217) | P-Value |
|---|---|---|---|
| Operative time (min) | 329 (166–695) | 342 (128–919) | 0.12 |
| Blood loss (ml) | 400 (20–7798) | 442 (10–4976) | 0.22 |
| Postoperative hospital days (day) | 12 (3–206) | 12 (4–194) | 0.32 |
| Max AST (U/L) | 331 (120–2042) | 393 (69–3519) | <0.05 |
| Clavien-Dindo grade ≥ III; Yes/No | 20 (12%)/137 | 37 (17%)/180 | 0.25 |
| Respiratory complication; Yes/No | 17 (10%)/140 | 29 (13%)/188 | 0.46 |
| PHLF; Yes/No | 58 (36%)/99 | 69 (31%)/148 | 0.29 |
| Perioperative mortality; Yes/No | 1 (0.006%)/156 | 5 (0.02%)/212 | 0.20 |
| VAS score POD1 (at rest) | 22.5 (0–100) | 20 (0–100) | <0.05 |
| VAS score POD2 (at rest) | 20 (0–100) | 14 (0–100) | 0.05 |
| VAS score POD3 (at rest) | 15 (0–83) | 10 (0–82) | 0.28 |
| VAS score POD1 (during movement) | 61 (0–100) | 50 (0–100) | <0.01 |
| VAS score POD2 (during movement) | 56 (0–100) | 48 (0–100) | <0.05 |
| VAS score POD3 (during movement) | 51 (0–100) | 45 (0–100) | <0.01 |
The 1st Era group (L-shaped incision: n = 123; Midline incision: n = 7; Laparoscopic surgery: n = 27) comprised patients who underwent procedures prior to the institutional policy change. The 2nd Era group (L-shaped incision: n = 66; Midline incision: n = 109; Laparoscopic surgery: n = 42) comprised patients who underwent procedures after the policy change.
AST, aspartate aminotransferase; PHLF, post-hepatectomy liver failure; VAS, visual analog scale; POD, postoperative day.
[median, (range)].
Clinical characteristics of patients in the 1st L-shaped and 2nd Midline groups after propensity score matching.
| Variables | Group 1st | Group 2nd Midline (n = 75) | P-Value |
|---|---|---|---|
| Age | 70 (45–88) | 71 (38–88) | 0.85 |
| Sex; Male/Female | 59/16 | 50/25 | 0.09 |
| BMI | 22.8 (16.9–37.3) | 22.6 (16.1–31.8) | 0.70 |
| DM; Yes/No | 25/29 | 22/37 | 0.33 |
| T-Bil (mg/dl) | 0.8 (0.3–1.9) | 0.8 (0.3–2.7) | 0.99 |
| AST (IU/l) | 37 (12–151) | 31 (12–91) | 0.08 |
| Albumin (mg/dl) | 4.0 (2.5–5.1) | 4.0 (2.7–4.9) | 0.77 |
| Prothrombin time (%) | 85 (66–112) | 89 (49–119) | 0.86 |
| ICGR-15 (%) | 14.0 (3.5–79.1) | 13.5 (3.1–54.6) | 0.61 |
| Child-Pugh classification; A/B | 73/2 | 71/4 | 0.40 |
| AFP (ng/ml) | 12.7 (0.5–2226) | 7.1 (0.5–23800) | 0.20 |
| Tumor size (mm) | 25 (8–170) | 25 (10–160) | 0.53 |
| Tumor number; Single/Multiple | 48/27 | 47/28 | 0.86 |
| Liver cirrhosis; Yes/No | 17/58 | 18/57 | 0.84 |
| Posterior region; Yes/No | 35/40 | 39/36 | 0.51 |
| Resected weight (g) | 156 (12–2332) | 136 (6–974) | 0.44 |
| Type of hepatectomy; Anatomical/Limited | 59/16 | 56/19 | 0.56 |
| Type of hepatectomy; Major/Minor | 3/72 | 7/68 | 0.19 |
| Perioperative pain management; Epi-PCA/iv-PCA | 42/33 | 39/36 | 0.62 |
The 1st L-shaped group (1st L group) included those who may have been eligible to undergo a midline incision but underwent procedures that used L-shaped incisions. The 2nd midline group (2nd M group) included those who underwent procedures utilizing a midline incision.
BMI, body mass index; DM, diabetes mellitus; T-Bil, total bilirubin; AST, aspartate aminotransferase; ALT, alanine transaminase; ICGR-15, indocyanine green retention rate at 15 min; AFP, α-fetoprotein; Epi-PCA, epidural–patient-controlled analgesia; iv-PCA, intravenous–patient-controlled analgesia.
[median, (range)].
Surgical and postoperative outcomes in the 1st L-shaped and 2nd Midline groups after propensity score matching.
| Variables | Group 1st | Group 2nd Midline (n = 75) | P-Value |
|---|---|---|---|
| Operative time (min) | 323 (166–537) | 330 (128–919) | 0.34 |
| Blood loss (ml) | 469 (50–4470) | 448 (20–4045) | 0.66 |
| Postoperative hospital days (day) | 12 (3–206) | 12 (8–93) | 0.58 |
| Max AST (U/L) | 336 (121–2042) | 379 (69–2667) | 0.85 |
| Clavien-Dindo grade ≥ III; Yes/No | 9 (12%)/66 | 13 (17%)/62 | 0.35 |
| Respiratory complication; Yes/No | 6 (8%)/69 | 10 (13%)/65 | 0.29 |
| PHLF; Yes/No | 30 (40%)/45 | 25 (33%)/50 | 0.39 |
| VAS score POD1 (at rest) | 22 (0–100) | 15 (0–86) | <0.05 |
| VAS score POD2 (at rest) | 20 (0–80) | 10.5 (0–80) | <0.05 |
| VAS score POD3 (at rest) | 12 (0–83) | 7 (0–60) | 0.24 |
| VAS score POD1 (during movement) | 53 (0–100) | 41 (0–100) | <0.01 |
| VAS score POD2 (during movement) | 56 (0–100) | 44.5 (0–100) | <0.05 |
| VAS score POD3 (during movement) | 50 (0–95) | 40 (0–100) | <0.01 |
The 1st L-shaped group (1st L group) included those who may have been eligible to undergo a midline incision but underwent procedures that used L-shaped incisions. The 2nd midline group (2nd M group) included those who underwent procedures utilizing a midline incision.
AST, aspartate aminotransferase; PHLF, post-hepatectomy liver failure; VAS, visual analog scale; POD, postoperative day.
[median, (range)].
Risk factors for transition from midline to L-shaped incisions according to univariate and multivariate analyses.
| Univariate analysis | Multivariate analysis | ||||||
|---|---|---|---|---|---|---|---|
| Factors | Category | 2nd Era Midline | 2nd Era L-shaped | P-Value | Odds Ratio | 95% CI | P-Value |
| Age | <75 | 71 (66%) | 47 (71%) | 0.40 | |||
| ≥75 | 38 (34%) | 19 (29%) | |||||
| Sex | Male | 76 (70%) | 60 (90%) | <0.01 | 3.36 | 1.22–9.26 | <0.05 |
| Female | 33 (30%) | 6 (10%) | |||||
| BMI | <23 | 55 (50%) | 22 (33%) | <0.05 | 1.87 | 0.91–3.82 | 0.08 |
| ≥23 | 54 (50%) | 44 (67%) | |||||
| Tumor size | <30 mm | 73 (67%) | 20 (30%) | <0.01 | 4.5 | 2.11–9.58 | <0.01 |
| ≥30 mm | 36 (33%) | 46 (70%) | |||||
| Tumor number | Single | 71 (65%) | 33 (50%) | <0.05 | 1.51 | 0.74–3.07 | 0.25 |
| Multiple | 38 (35%) | 33 (50%) | |||||
| Posterior resection | Yes | 53 (49%) | 40(61%) | 0.12 | |||
| No | 56 (51%) | 26 (39%) | |||||
| Excision range | Anatomical | 86 (79%) | 57 (86%) | 0.20 | |||
| Limited | 23 (21%) | 9 (14%) | |||||
| Liver Cirrhosis | Present | 22 (20%) | 12 (18%) | 0.74 | |||
| Absent | 87 (80%) | 54 (82%) | |||||
| HBV | Positive | 15 (14%) | 6 (10%) | 0.35 | |||
| Negative | 94 (86%) | 60 (90%) | |||||
| HCV | Positive | 59 (54%) | 21 (32%) | <0.01 | 1.95 | 0.92–4.10 | 0.07 |
| Negative | 50 (46%) | 45 (68%) | |||||
| Liver damage | A | 89 (82%) | 45 (68%) | <0.05 | 2.43 | 1.05–5.58 | <0.05 |
| B | 20 (18%) | 21 (32%) | |||||
| Type of Hx | Major | 9 (8%) | 13 (20%) | <0.05 | 1.26 | 0.44–3.59 | 0.65 |
| Minor | 100 (92%) | 53 (80%) | |||||
*BMI, Body mass index; HBV, hepatitis B Virus; HCV, hepatitis C virus; CI, confidence interval.